Research suggests symptomatic Alzheimer's treatments may reduce care costs

July 25, 2016

New research has linked the use of existing treatments for Alzheimer's to lower healthcare costs and increased survival for people with the disease. The study, which examined the impact of medications used to treat the symptoms of Alzheimer's, is presented at the Alzheimer's Association International Conference 2016 today (Monday 25 July).

The US study, from pharmaceutical company Merck, looked at the records of 1,338 people with Alzheimer's, half of whom had been prescribed treatments for the disease, and half of whom had not. Existing treatments do not stop or slow the course of the disease, but are used to help people cope with some of the symptoms.

The results showed that people who had never been prescribed an Alzheimer's treatment tended to be older, with more severe health conditions in addition to Alzheimer's. The death rate among this group was almost twice as high as those who received a treatment, and those not on these medications had higher monthly healthcare costs overall, averaging $2,349 per month compared to $2,207.

Dr Matthew Norton, Head of Policy at Alzheimer's Research UK, the UK's leading dementia research charity, said:

"Existing treatments for Alzheimer's are more effective for some people than for others, and while it's unclear whether the people in this study who were not prescribed these drugs could have benefited, many people with the disease find that symptomatic treatments can boost their quality of life. This research suggests that these treatments may also be associated with lower healthcare costs in the US, and while the healthcare system in this study is different to the UK's, the results further underline the importance of these medications.

"Recent evidence has highlighted differences in prescribing rates for Alzheimer's drugs across the UK, and it is crucial for this disparity to be addressed to ensure that everyone has the same access to treatments that may help them. In the meantime, we still need better treatments to tackle this devastating disease, and we must continue to invest in research to achieve this goal."

Explore further: Dementia treatments less likely to be prescribed in poorer areas of England

Related Stories

Dementia treatments less likely to be prescribed in poorer areas of England

November 19, 2015
The study, which also shows that these inequalities in England are not replicated in other parts of the UK, is published in the journal Age and Ageing.

Diabetes drug could influence brain activity in Alzheimer's

April 28, 2016
Researchers in Denmark have released findings from a small clinical trial of the diabetes drug liraglutide in people living with Alzheimer's disease.

Alzheimer's researchers investigate diabetes link in mice

June 22, 2016
Researchers in Aberdeen have highlighted a possible new link between Alzheimer's disease and diabetes according to a new study published today in the journal Diabetologia.

Antidepressant use begins years before Alzheimer's diagnosis

March 4, 2016
Antidepressants are frequently prescribed to persons with Alzheimer's disease before the diagnosis, according to a recent study from the University of Eastern Finland. Among persons with Alzheimer's disease, the initiation ...

New link found between diabetes and Alzheimer's disease

June 21, 2016
Drugs used to treat diabetes could also be used to treat Alzheimer's disease, and vice versa, according to new research from the University of Aberdeen.

Changes in blood flow to the brain may be early feature of Alzheimer's disease

June 22, 2016
A new study has shown that changes in blood flow to different brain areas may be one of the earliest changes in the brain linked to Alzheimer's disease. The research is published today in the journal Nature Communications.

Recommended for you

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

Biomarker may predict early Alzheimer's disease

November 10, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer's disease (AD). The discovery, published in Nature Communications, may ...

Smell test challenge suggests clinical benefit for some before development of Alzheimer's

November 10, 2017
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) may have discovered a way to use a patient's sense of smell to treat Alzheimer's disease before it ever develops. ...

How SORLA protects against Alzheimer's disease

November 7, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new protective function for a brain protein genetically linked to Alzheimer's. The findings, published in the Journal of Experimental ...

Saving neurons may offer new approach for treating Alzheimer's disease

November 6, 2017
Treatment with a neuroprotective compound that saves brain cells from dying also prevents the development of depression-like behavior and the later onset of memory and learning problems in a rat model of Alzheimer's disease. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.